Tapestry Pharmaceuticals to Sell Genomics Assets; Job Cuts to Total 25 Percent | GenomeWeb

NEW YORK, Nov. 18 (GenomeWeb News) - Tapestry Pharmaceuticals, formerlly known as NaPro BioTherapeutics, will close most of its genomics division by the end of next year, laying off around 20 people as it closes the division's facility and sells off or licenses out most of its assets, the firm said yesterday in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.

The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.

The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.

In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.